Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22692100 | 0.87 | SIGMAR1 (0.40) | SIGMAR1MCL1HDAC9PARP1HTR2A | |
| SCHEMBL29423684 | 0.84 | HTR1A (0.35) | SIGMAR1EPHX2ATM | |
| SCHEMBL22691990 | 0.82 | DRD2 (0.37) | ADRA2A | |
| SCHEMBL22692088 | 0.82 | DRD2 (0.37) | ADRA2A | |
| SCHEMBL22692123 | 0.77 | NOTUM (0.34) | SIGMAR1HTR2AHTR2CHRH1HTR2B | |
| SCHEMBL23385946 | 0.74 | CYP1A2 (0.36) | HTR2AHTR2CHRH1HTR2BALDH1A1 | |
| SCHEMBL29656734 | 0.74 | CYP1A2 (0.36) | HTR2AHTR2CHRH1HTR2BALDH1A1 | |
| SCHEMBL22709889 | 0.74 | HCN1 (0.36) | SIGMAR1HTR2AHTR2CHRH1HTR2B | |
| SCHEMBL29423697 | 0.74 | HCN1 (0.36) | SIGMAR1HTR2AHTR2CHRH1HTR2B | |
| SCHEMBL6505565 | 0.73 | GRM8 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227738-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-07-21 | — | — | US | disclosed |
| WO-2022115439-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-02 | — | — | WO | disclosed |
| EP-3972978-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2020236940-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227738-A1 | KRAS G12C INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | SIGMAR1 4782/4885MCL1 157/4885HDAC9 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.